Search

Your search keyword '"Koralewski P"' showing total 252 results
Start Over Author "Koralewski P"
252 results on '"Koralewski P"'

52. Abstract of the 68th Meeting (Spring Meeting) 6–9 March 1990, Heidelberg

Author

Sakmann, B., Schrader, J., Brenner, B., Murer, H., Boeckh, J., Handwerker, H. O., HonerjÄger, P., Dugas, M., Wang, G., DeLuca, A., Brinkmeier, H., Fakler, B., Pröbstle, T., Rüdel, R., Pohl, J. -A., Meves, H., Kroll, B., Bremer, S., Tümmler, B., Frömter, E., Schwegler, J. S., Steigner, W., Silbernagl, S., Pusch, Michael, Niemann, P., Schmidtmayer, J., Ulbricht, W., Hansen, G., Lönnendonker, U., Neumcke, B., Eickhorn, R., Hornung, D., Antoni, H., Penner, R., Neher, E., Takeshima, H., Nishimura, S., Numa, S., Melzer, W., Feldmeyer, D., Pohl, B., Zöllner, P., Müller, T. H., Swandulla, D., Misgeld, U, Ganitkevich, V. Ya., Isenberg, G., Cavalié, A., Allen, T. J. A., Trautwein, W., Pelzer, Siegried, Shuba, Yaroslav M., Asai, Tatsuya, Trautwein, Wolfgang, Brown, Arthur M., Birnbauner, Lutz, McDonald, Terence F., Pelzer, Dieter, Eckert, R., Hescheler, J., Rosenthal, W., Offermann, S., Krautwurst, D., Schultz, G., Kettenmahn, Helmut, Trotter, J., Verkhratsky, Alexe J N., Savtchenko, Alexej N., Verkhratsky, Alexej N., Schiefer, A., Klöckner, U., Partridge, L. D., SchÄfer, S., Jonas, P., Koh, D. S., Kampe, K., Hermsteiner, M., Vogel, W., Bauer, C. K., Schwarz, J. R., Fink, R. H. A., Wettwer, E., Weik, R., Schlatter, E., Bleich, M., Granitzer, M., Leal, T., Nagel, W., Crabbé, J., Lang, F., Kahn, E., Friedrich, F., Paulmichl, M., Hammerer, M., Maly, K., Grunicke, H., Böhm, T., Nilius, B., Gögelein, H., Dahlem, D., Weiss, H., Waldegger, S., Woell, E., Paulmichl, R., Ruppersberg, J. P., Schröter, K. H., Stocker, M., Pongs, O., Wittka, R., Boheim, G., Lichtinghagen, R, Augustine, C. K., Stühmer, W., Hoppe, Dorothe, Hoppe, D., Zittlau, K. E., Walther, C., Hatt, H., Franke, C., Quasthoff, S., Wischmeyer, E., Jockusch, H., Friedrich, M., Benndorf, K., Bollmann, G., Hirche, Hj., Hollunder-Reese, F., Mohrmann, M., Greger, R., Weber-Schürholz, S., Schürholz, T., Akabas, M., Landry, D., Al-Awqati, Q., Guse, A. H., Gercken, G., Meyerhof, W., Westphale, H. -J., Kerstins, U., Oberleithner, H., Tilmann, M., Kunzelmann, K., Klitsch, T., Siemen, D., Draguhn, A., Verdoorn, T. A., Pritchett, D. B., Seeburg, P. H., Malherbe, P., Möhler, H., Sakmann, B., Hatt H., Dudel, J., Stern, P., Zufall, F., Rosenheimer, J., Smith, D. O., Dörner, R., Ballanyi, K., Schlue, W. -R., Kalthof, B., Pott, L., Busch, C., Konno, T., Stenql, M., Reinhardt, Ch., Kaiser, H., Baumann, R., Wilimzig, M., Eichenlaub, R., Neumann, E., Lessmann, V., Gottmann, K., Dietzel, I. D., Keller, B. U., Yaari, Y., Konnerth, A., Backus, K. H., Giller, T., Knoflach, F., Pflimlin, P., Trübe, G., von Blankenfeld, G., Ymer, S., Sontheimer, H., Ewert, M., Seeburg, P. H., Kettenmann, H., Schneggenburger, R., Paschke, D., Hülser, D. F., Ubl, J., Kolb, H. A., Ströttchen, J., Boheim, S., Wehner, F., Guth, D., Kinne, R. K. H., Hülser, D. F., Polder, H. R., Bödeker, D., Hoppe, Susanne, Höller, H., Hampe, W., Ruf, H., Schulz, I., Dehlinger-Kremer, M., Ozawa, T., Vasilets, L., Schmalzing, G., MÄdefessel, K., Biel, H., Schwarz, W., Burckhardt, B. C., Stallmach, N., MairbÄurl, H., Hoffman, J. F., Schömig, E., Heuner, A., Göbel, B. O., Siffert, W., Butke, A., Hoffmann, G., zu Brickwedde, M. -K. Meyer, Vetter, H., Düsing, R., Rosskopf, D., Osswald, U., Steffgen, J., Koepsell, H., Martens, H., Rübbelke, M., GÄbel, G., Arens, J., Stabel, J., Fischer, Y., Thomas, J., Rose, H., Kammermeier, H., Munsch, Thomas, Deitmer, Joachim W., Engelmann, B., Duhm, J., Deitmer, Joachim W., Gunzel, D., Galler, S., Fischer, H., Clauss, W., Van Driessche, W., Köckerling, A, Schulzke, JD, Sorgenfrei, D, Fromm, M, Simon, B., Ganapathy, V., Leibach, F. H., Burckhardt, G., Krattenmacher, R., Voigt, Rosita, Dietrich, S., Leyssens, A., Zhang, S. L., Weltens, R., Steels, P., Hoffmann, B., Heinz, M., Habura, B., Dörge, A., Rechkemmer, G., von Engelhardt, W., StrauB, O., Wiederholt, M., Margineanu, D. -G., Van Driessche, W., Kreusel, K. M., Fromm, M., Lempart, U., Sorgenfrei, D., Hegel, U., Augustin, A. J., . Goldstein, R., Purucker, E., Lutz, J., Illek, B., Thiele, K -P., Schwealer, JS., Dittmer J., Bauer C., Eckardt, K. -U., Dittmer, J., Neumann, R., Bauer, C., Kurtz, A., Fromm, H., Schulzke, J. D., Clausen, P., Krohn, A., Lüderitz, S., Hierholzer, K., Kersting, U., Woinowski, L., Gro\mann, R., Bin, X. U., Ellendorff, F., Nitschke, R., Fröbe, U., Scholz, H., della Bruna, R., Ehmke, H., Persson, P. B., Seyfarth, M., Kirchheim, H. R., Dietrich, M. S., Parekh, N., Steinhausen, M., Bührle, C. P., Nobiling, R., Ullrich, K. J., Rumrich, G., Klöss, S., Papavassiliou, F., Hoyer, J., Schmitt, C., Jungwirth, A., Ritter, M., Westphale, H. J., Bevan, C., Theiss, C., Denek, Liliana, Schwegler, Johann S., SchÄfer, Roland, Augustin, Albert J., Heidland, August, Nafz, B., Just, A., Steidl, M., Pinggera, G., Gerstberger, R., Schütz, H., Simon, E., Lohrmann, E., Masereel, B., Delarge, J., Lang, H. J., Englert, H. C., Caliebe, D., Mályusz, M., Wrigge, P., Gronow, G., Klause N., Mályusz, M., Zinnert, H., Fagel, H., Jelkmann, W., Weiss, Ch., Augustin, A. J., Keil, R., Schmidt, W., Kröger, C., Brabant, E. G., Hilgendorf, A., Strauch, S., Lane, F., Prick, A., Golenhofen, N., Mildenberger, S., Schwegler, J. S., Flemming, B., Roloff, D., Wronski, T., Drews, G., Debuyser, A., Henquin, J. C., Jackson, M. B., DeRiemer, S. A., Schmid, A., Schnefel, S., Pröfrock, A., Hinsch, K. -D., Milz, J., Lamprecht, G., Seidler, U., Silen, W., Aziz, O., Reschke, W., Fischer, G., De Decker, N., Hayes, T., Coast, G., Van Kerkhove, E., von zur Mühlen, F., Eckstein, F., Hegel, U, Bentzel, CJ, Riecken, EO, Siemer, C., Rothenpieler, P., Smith, E., Lutnicki, K. R., Wróbel, J. T., Ledwożyw, A., PietraŚ, E., Sender, S., Jürgens, Klaus D., Kleinschmidt, T., Werkmeister, F., Kiwull-Schöne, H., Kiwull, P., Vahle, J., Ott, M., Zimmermann, R. E., Elsing, J. G., Million, D., Zillner, P., Thiel, M., Bardenheuer, H., Peter, K., Fandrey, J., Siegers, C. P., Rupp, H., Elimban, V., Dhalla, N. S., Morano, I., Agostini, B., Mühleisen, M., Mommaerts, W. F. H. M., Ono, K., Wussling, M., Schenk, W., Boldt, W., Lipp, P., Schüttler, K., Szymanski, G., Wendt-Gallitelli, M. F., Herzig, J. W., Depersin, H., Grupp, G., Grupp, I., Glitsch, H. G., Pusch, H., Zylka, Ch., Brāndle, M., Jacob, R., Stein, T., Isselhard, W., Sturz, J., Minor, T., Wingenfeld, P., Siegmund, B., Klietz, T., Schwartz, P., Piper, H. M., Linder, Christa, SchÄfer, Stefan, Heusch, Gerd, Becker, B. F., Reinholz, N., Raschke, P., Leipert, B., Gerlach, E., Dierberger, B., Gülch, R. W., Leverkus, M., Mitsuiye, T., Pohl, U., Wang, S. Y., Meyer, R., Haas, H. G., Christmann, H. Ph, Dörner, Th, Hock, D., Hertel, R., Gagelmann, M., Forssmann, W. G., Leijendekker, W. J., Kissling, G., Michel, H., Goetz, A., Freya, M., Fleckenstein-Grün, G., Schipke, Jochen D., Harasawa, Yasuhiko, Sugiura, Seiryo, Alexander, Joe, Burkhoff, Daniel, Kling, L., Müller-Beckmann, B., Schroth, M., Sponer, G., Böhm, E., Strein, K., Dorszewski, A., Arnold, G., Pike, G. K., Bryant, D. J., Roberts, M. L., Fink, R. H., Ross, Ch., Skyschally, A., Schulz, R., Linder, C., Heusch, G., Schipke, J. D., Burkhoff, D., Alexander, J., Gollnick, F., Peter, Kh., Franken-Weyers, R., Borst, M. M., Deussen, A., Pöpping, S., Hose, H., Strotmann, K. H., Lukascek, B., Karnath, T., Güttier, K., Klaus, W., Haverkampf, K., Guhlmann, M., Schmidt-Ott, S., Heuschen, U., Mall, G., Pfitzer, G., Rösch, J., Arner, A., Rüegg, J. C., Kröger, K., Schipke, J. D., ThÄmer, V., Ehring, Thomas, ThÄmer, Volker, Guth, B. D., Schnabel, Ph A., Schmiedl, A., Gebhard, M. M., Richter, J., Bretschneider, H. J., Guth, B. D., Oudiz, R. J., Schnabel, Ph., Richter, J ., Watanabe, H., Spahr, R., Piper, H. M., Obst, O., Mertens, H., Mülsch, A., Busse, R., Lamontagne, D., Herlan, K., Huang, A., Bassenae, E., Mackert, J. R. L., Schilling, L., Parsons, A. A., Wahl, M., Hock, D., Christmann, M. Ph., Thimm, F., Frey, M., Fleckenstein, a. A., Theilen, H., Göbel, U., Kuschinsky, W., Elbert, Th., Tafil-Klawe, M., Rau, H., Lutzenberger, W., Fleckenstein, A., Forst, H., Haller, M., Santjohanser, C., Lauterjung, L., Smieško, Y., Lang, D. J., Johnson, P. C., Schröck, H., Rau H., Elbert T., Geiger B, Lutzenberger W., Koch, G., Koralewski, H. E., Perschel, F. H., Wagner, K., Krüger, U., Albrecht, M., Hohlbach, G., Maassen, N., Foerster, M., Mühling, J., Bari, F., Pleschka, K., Schmidt, H. D., Gro\, H., Loock, W., Stick, C., Diefenbacher, U., Gronewold, D., Tobinsky, M., Walther-Behrends, A., Witzleb, E., Brummermann, M., Reinertsen, R. E., Rogausch, H., Rohn, W. M., Acker, H., Delpiano, M., Dufau, E., Hentschel, J., Heller, H., Schuster, K. -D., Siekmeier, R., Kronenberger, H., Lintl, H., Schiller-Scotland, Ch. F., Gebhart, J., Heyder, J., Meier-Sydow, J., Stahlhofen, W., Mottaghy, K., Geisen, C., Richter, W., Beckman, J., Marek, W., Ulmer, W. T., Thiele, A. E., Raschke, F., Peter, J. H., Hildebrandt, G., Kullmer, T., Kozianka-Burghof, G., Thiele, A. E., Schlaefke, M. E., Gnuschke, H., Schaefer, T., Schaefer, D., Schaefer, C., Bradley, Ronald J., Sterz, Raimund, Peper, Klaus, Benterbusch, R., Kraft, Th., Yu, L. C., Kuhn, H. J., Blankenbach, K., Asmussen, G., Kunze, I., Pieper, K. -S., Steinmetz, J., Schmidt, H., Krippeit-Drews, P., Hübschen, U., Nacimiento, A. C., Günzel, D., Rathmayer, W., Gaunitz, U., Költgen, D., Zachar, E., Soltau, B., De Martino, L., Hasselbach, W., Kössler, F., Lange, P., Küchler, G., Zeugner, C., Van Eyk, J., Hodges, R. S., Lorkovic, H., Clemens, N., Scheid, P., Noack, Th., Deitmer, P., Golenhofen, K., Lammel, E., Welling, Andrea, Felbel, Jochen, Hofmann, Franz, Katoch, S., Watanabe, T., Mandrek, K., Milenov, K., Hammer, K., Rössler, W., Sann, H., Pierau, Fr -K., Nguyen-Duong, H., Schneider, P., Stahl, F., Lepple-Wienhues, A., Korbmacher, C., Haller, H., Gebauer, M., Willner, U., Bialojan, C., Lengsfeld, M., Kyrtatas, V., Dartsch, Peter C., Boels, P. J., Fischer, W., Lenz, T., Thei\, U., Kreye, V. A. W., Ohkubo, T., Kupp, H., Vonderlage, M., Schreiner, V., Dorlöchter, M., Brinkers, M., Irintchev, A., Wernig, A., Langenfeld, B., Finger, W., Wolburg, H., Beer, A., Schwejda, Ch., Scheller, D., Heister, U., Tegtmeier, F., Knöpfel, Thomas, Spuler, Andreas, Grafe, Peter, GÄhwiler, Beat, Bijak, M., Misgeld, U., Müller, W., Rausche, G., Leweke, F M., Bingmann, D., Moraidis, I., Speckmann, E. -J., Madeja, M., Mu\hoff, U., Lehmenkühler, A, Kuhlmann, D., Hans, M., Lux, H. D., StrÄub, H., Waiden, J., Baker, R. E., Grantyn, R., Perouansky, M., Kraszewski, K, Lehmenkühler, Chr, Dodt, H. U., ZieglgÄnsberger, W., Pawelzik, H., ZieglgÄngsberger, W., Mann, K., Wiethölter, H., Albrecht, D., Dreier, J., Ficker, E., Beck, H., Corrette, B J., Dreyer, F., Repp, H., Dreessen, J., Augustine, G. J., Lehmenkühler, A., Büsselberg, D., Heimrich, B., Haas, H. L., Birnstiel, S., Haas, H. L., Schönrock, B., Altrup, U., Reith, H., Speckmann, E. -J., Alzheimer, C., Bruagencate, G. ten, Fruhstorfer, B., Mignot, E., Nishino, S., Dement, W. C., Guilleminault, C., Simon-Oppermann, Christa, Günther, Olaf, Stehle, J., Reuss, S., Seidel, A., Riemann, R., Vollrath, L., Reimer, Susanne, HölIt, Volker, Sonnhof, U., Krupp, J., Claus, H, Hinckel, P., Dick, H. B. H., Hiemke, C., Jussofie, A., Dorn, T., Uhlig, S., Witte, O. W., Bother B., Eiselt M., Witte H., Zwiener ö, Rother M, Eiseit H., Taghavy, A., KrÄtzer, A., Clusmann, H., Heinemann, U., Block, F., Sonatg, K. -H., Falkeristein, M., Hohnsbein, J., Hoormann, J., Frieling, A., Tarkka, I. M., Kullmann, W., Bromm, B., Hirsch, M. Chr, Wissing, H., Braun, H. A., Igelmund, P., Klu\mann, F. W., Ehrenstein, W. H., Yakimoff, N., Mateeff, S., Zeise, M. L., Arriagada, J., Teschemacher, A., ZieglgÄnsberger, W., Pöppelmann, T., Köhling, R., Boerrigter, P., Reith, H., Anders, K., Ohndorf, W., Dermietzel, R., Richter, D. W., Tölle, T. R., Castro-Lopes, J. M., Neuropharmakologie, Klinische, Sandkühler, J., Leah, J. D., Herdegen, T., Zimmermann, M., Vaitl, D., Gnippe, H., Herbert, M. K., Mengel, M. K. C., Kniffki, K. -D., Linke, R., Vahle-Hinz, C., Schenda, J., Matsumura, K., Herdegen, T., fu, Q. -G., Forster, C., Hutchison, W. D., Morton, C. R., Aschoff, J., Wilhelm, Z., Schwarzacher, S. W., Wasserschaff, M, Hörner, M., Kümmel, H., Windhorst, U., Feldman, J. L., Schmid, K., Foutz, A. S., Denavit-Saubié, M., Pak, M. A., Wehling, P., Evans, C., Bandara, G., Awiszus, F., Feistner, H., Heinze, H. -J., Illert, M., Wasserschaff, M., Kleinebeckel, D., Böhmer, G., Schauer, W., Abel, H. -H., Klü\endorf, D., Koepchen, H. P., Jarolimek, W, König, St, Czachurski, J., Seller, H., Meckler, R. L., McLachlan, E. M., Boczek-Funcke, A., HÄbler, H. -J., JÄnig, W., Michaelis, M., Dembowsky, K., Königr, S., Rau, Harald, HÄbler, H. -J., Unger, M., Merker, G., Roth, J., Zeisberger, E., Gao, H., Hunold, M., Kirchner, F., Takano, K., Schulze, K., Pokorski, M., Sakakibara, Y., Masuda, A., Morikawa, T., Ahn, B., Takaishi, S., Paulev, P. -E., Honda, Y., Flügge, G., Fuchs, E., König, S., Eysel, U. Th., Schmidt-Kastner, R., Skrandies, W., Geib, T., Baumann, C., Schmidt, K. -F., Knapp, A. G., Dowling, J. E., Kuba, M., Toyonaga, N., Kubová, Z., Ehrenstein, W. H., Jacobi, P., Schmidt, K. -F., Nöll, G. N., Baumann, Ch., Tabata, M., Martin, Ch., Meissl, H., Knottenberg, Th., Scheibner, H., Zenner, Hans P., Zimmennann, Ulrike, Gitter, Alfred H., Ding, D., Smolders, J. W. T., Klinke, R., Boekhoff, I., Raming, K., Krieger, J., Tareilus, E., Strotinann, J., Breer, H., Schild, D., DeSimone, J. A., Hellwig, S., Gitter, A. H., Plinkert, P. K., Zenner, H. P., Koltzenbwg, M., Pinter, E., SchÄfer, K., Braun, H. A., Necker, R., Hanesch, U., Heppelmann, B., Schmidt, R. F., Mense, S., Hoheisel, U., Steen, K. H., Anton, F., Reek, P. W., Handwerker, H. O., Lewin, G. R., McMahon, S. B., Heyer, G., Hornstein, O. P., Klement, W., Arndt, J. O., Maeerl, W., GrÄmer, G., Schepelmann, K., Me\linger, K., Schaible, H. -G., Treede, R. D., Meyer, R. A., Campbell, J. N., Claus, D., Neundörfer, B., Ernst, R., Tick-Waider, A. M., Bretschneider, F., Peters, R. C., Tennis, P. F. M., Teunis, P. F. M., Hoheisel, D., Scherotzke, R., Bub, A., Manzl, G., Forssmann, W. G., Jessen, C., Nuesslein, B., Schmidt, I., Wetzig, J., Reiser, M., Bregenzer, N., von Baumgarten, R. J., Mohr, E., Krzywanek, H., Warncke, G., Schuchmann, K. -L., Linow, H., Klu\mann, F. H., Redlin, U., Heldmaier, G., Bamler, A, Koller, A., Felber, S., Haid, C., Wicke, K., Raas, E., Xuemin, Wang, Kerning, Chen, Ying, Shi, Hanping, Shi, Warncke, Günther, Voisord, R., Dortsch, P. C., Betz, E., Karbach, U., Walenta, S., Gross, M. W., Mueller-Klieser, W., Vaupel, P., Okunieff, P., Mayer, W. -K., Stohrer, M., Krüger, W., Müller-Klieser, W., Strupp, M., Weial, P., Bostock, H., Piwernetz, K., Renner, R., Grafe, P., Lankers, J., Zangemeister, W., Kunze, K., Tries, S., Heinle, H., Beckerath, N. V., Maier-Rudolph, W., Mehrke, G., Günther, K., Goedel-Meinen, L., Daut, J., Piper, H. M., Kopp, A., Noll, T., Goellner, A., Gerlach, S., Teutsch, H. F., Schienger, K., Schwab, R., Höckel, M., Fotev, Z., Nienhaus, M., Kaczmarczyk, Gabriele, Richter, Dinah, Korte, Gabriele, Förther, J., Reinhardt, H. W., Schreiber, R., Rupp, J., Murphy, G., Fingerle, J., Kloiber, O., Miyazawa, T., Höhn-Berlage, M., Hossmann, K. -A., Schad, H., Heimisch, W., Blasini, R., Haas, F., Mendier, M., Spuler, A., Lehmann-Hom, F., Wolfram, U., Fenske, M., Sachser, N., Weis, Ch., Marktl, W., Kopta, B., Klammer, N., Rudas, B., Pohl, H., Nienartowicz, A., Moll, W., Klempt, M., Blum, S., Bühler, H., Lichtenstein, I., Novak, A., Siebe, H., Hierholzer, K., and Peper, K.

Published
1990
Full Text
View/download PDF

55. Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers

Author

Clingan, P.R., primary, Mant, A.M., additional, Richardson, G.E., additional, Kowalski, D.M., additional, Koralewski, P., additional, Lugowska, I., additional, Dechaphunkul, A., additional, Charoentum, C., additional, Sookprasert, A., additional, Sriuranpong, V., additional, Akopov, A., additional, Kozlov, V., additional, Fadeeva, N., additional, Kasparov, B., additional, Kovalenko, N.V., additional, Oschepkov, V., additional, Gorelik, L., additional, Kunes, Y., additional, Oliviero, J., additional, and Harris, D.L., additional

Published
2019
Full Text
View/download PDF

56. Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis.

Author

Koralewski, Robert, Dymek, Barbara, Mazur, Marzena, Sklepkiewicz, Piotr, Olejniczak, Sylwia, Czestkowski, Wojciech, Matyszewski, Krzysztof, Andryianau, Gleb, Niedziejko, Piotr, Kowalski, Michal, Gruza, Mariusz, Borek, Bartłomiej, Jedrzejczak, Karol, Bartoszewicz, Agnieszka, Pluta, Elżbieta, Rymaszewska, Aleksandra, Kania, Magdalena, Rejczak, Tomasz, Piasecka, Sylwia, and Mlacki, Michal

Published
2020
Full Text
View/download PDF

57. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Author

Ravaud, A, Motzer, Rj, Pandha, Hs, George, Dj, Pantuck, Aj, Patel, A, Chang, Yh, Escudier, B, Donskov, F, Magheli, A, Carteni, G, Laguerre, B, Tomczak, P, Breza, J, Gerletti, P, Lechuga, M1, Lin, X, Martini, Jf, Ramaswamy, K, Casey, M, Staehler, M, Patard, Jj, Gruenwald, V, Link, K, Doehn, C, Heinzer, H, Grimm, M-O, Wirth, M, Stoeckle, M, Heidenreich, A, Garcia del Muro Solans, X, Mellado, Bo, Castellano, Dg, Frydenberg, M, Schobinger, Sr, Dimopoulos, Ma, Rothermundt, C, Climent Duran MA, Melotti, B, Procopio, G, Boccardo, F, Sella, A, Stewart, S, Adenis, A, Jones, Rj, Chevreau, C, Prausova, J, Vyzula, R, Oudard, S, Jacqmin, D, Gravis, G, Varela, R, Herrmann, E, Lim, Hy, Lee, J-L, Kim, Yh, Kim, Jh, Y-C, Ou, Papakotoulas, P, Iacobelli, S, Chowdhury, S, Passalacqua, R, Tomasek, J, Anton Aparicio LM, Linassier, C, Hauser, S, Bergmann, L, Hawkins, Re, Szczylik, C, Zdrojowy, R, Sosnowski, M, Koralewski, P, Wiechnio, Pj, Schraml, J, Mardiak, J, Laurinc, P, Kliment, J, Rosenbaum, E, Lundstam, S, Flodgren, P, Ljungberg, B, Stenzl, A, Schnoeller, Tj, Mcdermott, Sr, Breathnach, Os, Mccaffrey, Ja, Donnellan, P, The, G-C, Rolland, F, Brekkan, E, Nilsson, C, Kim, Wy, Bishoff, J, Chung, J, Shore, Nd, Master, V, Tang Chen DY, Ye, D, Huang, Y, Jin, J, Song, B, Zhou, F, Galceran, Jc, Yao, X, and Zhang, X.

Subjects
Male, Indoles, medicine.medical_treatment, Clinical Trial, Phase III, 030232 urology & nephrology, Nephrectomy, 0302 clinical medicine, Renal cell carcinoma, Clinical endpoint, 80 and over, Adjuvant, Aged, 80 and over, Adolescent, Adult, Aged, Antineoplastic Agents, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Double-Blind Method, Drug Administration Schedule, Female, Humans, Kidney Neoplasms, Middle Aged, Pyrroles, Survival Analysis, Young Adult, Medicine (all), Sunitinib, General Medicine, Multicenter Study, 030220 oncology & carcinogenesis, Randomized Controlled Trial, medicine.drug, medicine.medical_specialty, Urology, Placebo, 03 medical and health sciences, Journal Article, Carcinoma, medicine, Chemotherapy, Survival analysis, business.industry, Renal Cell, medicine.disease, Surgery, Clinical trial, business
Abstract

BACKGROUNDSunitinib, a vascular endothelial growth factor pathway inhibitor, is an effectivetreatment for metastatic renal-cell carcinoma. We sought to determine the efficacyand safety of sunitinib in patients with locoregional renal-cell carcinoma athigh risk for tumor recurrence after nephrectomy.METHODSIn this randomized, double-blind, phase 3 trial, we assigned 615 patients withlocoregional, high-risk clear-cell renal-cell carcinoma to receive either sunitinib(50 mg per day) or placebo on a 4-weeks-on, 2-weeks-off schedule for 1 year oruntil disease recurrence, unacceptable toxicity, or consent withdrawal. The primaryend point was disease-free survival, according to blinded independent central review.Secondary end points included investigator-assessed disease-free survival,overall survival, and safety.RESULTSThe median duration of disease-free survival was 6.8 years (95% confidence interval[CI], 5.8 to not reached) in the sunitinib group and 5.6 years (95% CI, 3.8 to6.6) in the placebo group (hazard ratio, 0.76; 95% CI, 0.59 to 0.98; P=0.03). Overallsurvival data were not mature at the time of data cutoff. Dose reductions becauseof adverse events were more frequent in the sunitinib group than in theplacebo group (34.3% vs. 2%), as were dose interruptions (46.4% vs. 13.2%) anddiscontinuations (28.1% vs. 5.6%). Grade 3 or 4 adverse events were more frequentin the sunitinib group (48.4% for grade 3 events and 12.1% for grade 4 events)than in the placebo group (15.8% and 3.6%, respectively). There was a similarincidence of serious adverse events in the two groups (21.9% for sunitinib vs.17.1% for placebo); no deaths were attributed to toxic effects.CONCLUSIONSAmong patients with locoregional clear-cell renal-cell carcinoma at high risk fortumor recurrence after nephrectomy, the median duration of disease-free survivalwas significantly longer in the sunitinib group than in the placebo group, at a costof a higher rate of toxic events. (Funded by Pfizer; S-TRAC ClinicalTrials.gov number,NCT00375674.)

Published
2016

58. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

Author

Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E. L., Marschner, N., Maroun, J., Garcia-Alfonso, P., Tujakowski, J., Van Hazel, G., Wong, A., Zaluski, J., Twelves, C., Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E. L., Marschner, N., Maroun, J., Garcia-Alfonso, P., Tujakowski, J., Van Hazel, G., Wong, A., Zaluski, J., and Twelves, C.

Abstract

Background: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer. We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared with 5-FU/LV (Mayo Clinic regimen) in Dukes' C colon cancer. Patients and methods: Patients aged 18-75 years with resected Dukes' C colon carcinoma were randomized to receive 24 weeks of treatment with either oral capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days (n = 993), or i.v. bolus 5-FU 425 mg/m2 with i.v. leucovorin 20 mg/m2 on days 1-5, repeated every 28 days (n = 974). Results: Patients receiving capecitabine experienced significantly (P <0.001) less diarrhea, stomatitis, nausea/vomiting, alopecia and neutropenia, but more hand-foot syndrome than those receiving 5-FU/LV. Fewer patients receiving capecitabine experienced grade 3 or 4 neutropenia, febrile neutropenia/sepsis and stomatitis (P <0.001), although more experienced grade 3 hand-foot syndrome than those treated with 5-FU/LV (P <0.001). Capecitabine demonstrates a similar, favorable safety profile in patients aged <65 years or ≥65 years old. Conclusions: Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer. Efficacy results are expected to be available in 2004. Keywords: Adjuvant treatment, capecitabine, chemotherapy, colorectal cancer

Published
2017

59. Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases.

Author

Mazur, Marzena, Dymek, Barbara, Koralewski, Robert, Sklepkiewicz, Piotr, Olejniczak, Sylwia, Mazurkiewicz, Marcin, Piotrowicz, Michał, Salamon, Magdalena, Jędrzejczak, Karol, Zagozdzon, Agnieszka, Czestkowski, Wojciech, Matyszewski, Krzysztof, Borek, Bartłomiej, Bartoszewicz, Agnieszka, Pluta, Elżbieta, Rymaszewska, Aleksandra, Mozga, Witold, Stefaniak, Filip, Dobrzański, Paweł, and Dzwonek, Karolina

Published
2019
Full Text
View/download PDF

61. Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma

Author

Mazur, Marzena, Olczak, Jacek, Olejniczak, Sylwia, Koralewski, Robert, Czestkowski, Wojciech, Jedrzejczak, Anna, Golab, Jakub, Dzwonek, Karolina, Dymek, Barbara, Sklepkiewicz, Piotr L., Zagozdzon, Agnieszka, Noonan, Tom, Mahboubi, Keyvan, Conway, Bruce, Sheeler, Ryan, Beckett, Paul, Hungerford, William M., Podjarny, Alberto, Mitschler, Andre, Cousido-Siah, Alexandra, Fadel, Firas, and Golebiowski, Adam

Abstract

This article highlights our work toward the identification of a potent, selective, and efficacious acidic mammalian chitinase (AMCase) inhibitor. Rational design, guided by X-ray analysis of several inhibitors bound to human chitotriosidase (hCHIT1), led to the identification of compound 7fas a highly potent AMCase inhibitor (IC50values of 14 and 19 nM against human and mouse enzyme, respectively) and selective (>150× against mCHIT1) with very good PK properties. This compound dosed once daily at 30 mg/kg po showed significant anti-inflammatory efficacy in HDM-induced allergic airway inflammation in mice, reducing inflammatory cell influx in the BALF and total IgE concentration in plasma, which correlated with decrease of chitinolytic activity. Therapeutic efficacy of compound 7fin the clinically relevant aeroallergen-induced acute asthma model in mice provides a rationale for developing AMCase inhibitor for the treatment of asthma.

Published
2024
Full Text
View/download PDF

62. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non‒Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

Author

Yang, James Chih-Hsin, Han, Baohui, De La Mora Jiménez, Emmanuel, Lee, Jong-Seok, Koralewski, Piotr, Karadurmus, Nuri, Sugawara, Shunichi, Livi, Lorenzo, Basappa, Naveen S., Quantin, Xavier, Dudnik, Julia, Moran Ortiz, Diego, Mekhail, Tarek, Okpara, Chinyere E., Dutcus, Corina, Zimmer, Zachary, Samkari, Ayman, Bhagwati, Niyati, and Csőszi, Tibor

Abstract

Lenvatinib plus pembrolizumab demonstrated antitumor activity and acceptable safety in previously treated metastatic NSCLC. We evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in metastatic NSCLC in the LEAP-007 study (NCT03829332/NCT04676412).

Published
2024
Full Text
View/download PDF

66. Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma.

Author

Mazur, Marzena, Olczak, Jacek, Olejniczak, Sylwia, Koralewski, Robert, Czestkowski, Wojciech, Jedrzejczak, Anna, Golab, Jakub, Dzwonek, Karolina, Dymek, Barbara, Sklepkiewicz, Piotr L., Zagozdzon, Agnieszka, Noonan, Tom, Mahboubi, Keyvan, Conway, Bruce, Sheeler, Ryan, Beckett, Paul, Hungerford, William M., Podjarny, Alberto, Mitschler, Andre, and Cousido-Siah, Alexandra

Published
2018
Full Text
View/download PDF

67. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

Author

Mieog, Js, Morden, Jp, Bliss, Jm, Coombes, Rc, van de Velde CJ, IES Steering Committee: Delozier, T, Veronesi, A, Vrdoljak, E, Monnier, A, Coombes, C, Nagykalnai, T, Roumen, Rm, Utracka Hutka, B, Pluzanska, A, Porpiglia, M, Genta, F, Benedetto, Chiara, Sozzani, P, Steiner, M, Rubinov, R, Leviov, M, Semiglazov, V, Fox, J, Mayordomo, Ji, Cervek, J, Sleeboom, Hp, Jassem, J, Hinton, Cp, Paulsen, Th, Guleng, Rj, Fein, L, Gutulescu, N, Florián, J, Rosso, R, Rutgers, Ej, Krzakowski, M, Pienkowski, T, Krajina, Z, Siffnerova, H, Pawlicki, M, Drosik, K, Wagnerowa, M, Brunt, M, Vukelja, S, Mitrowic, L, Cataliotti, L, Karnicka Mlodkowska, H, Bonnefoi, H, Tilch, G, Chollet, P, Patel, A, Kamby, C, Giustini, L, Acito, L, Mouridsen, H, Roche, H, De Lafontan, B, Tomczak, P, Petruzelka, L, Lortholary, A, Pacquola, Mg, Skene, A, Rici, S, Michelotti, A, Ghilezan, N, Stewart, A, Beauduin, M, Andersen, J, Vassilaros, S, Celio, L, Bajetta, E, Bastús, R, Marsland, T, Paridaens, R, Tzekova, V, Lichtenegger, W, Piersma, H, Jones, S, Holmberg, S, Verhoeven, D, Hill, A, Porcile, G, Bruno, Mf, Chernozemski, I, Coleman, R, Jadeja, J, Cohn, A, Merlano, M, Perroni, D, Di Costanzo, F, Van Bochove, A, Gerrits, Ma, Malec, V, Balil, A, Mendiola, C, Dodwell, D, Knox, R, Horgan, K, Joannides, T, Leonard, Rc, Cawthorn, Sj, Ghosh, C, Cantrell, J, Campos, D, Orti, R, Diedrich, K, Aas, H, Barnadas, A, Vila, Mm, Makris, A, Anderson, T, Chittor, S, Michel, J, Philip, P, Redmond, P, Mastboom, Wj, Nordenskjöld, B, Simmonds, P, Grieve, Rj, Tomova, A, Piot, G, Borea, G, Ucci, G, Einarsson, E, Nicholson, S, Gardiol, Ea, Kerger, J, Schlosser, J, Namer, M, Pinotti, G, Rutten, Ht, Iversen, T, Nejim, A, Dudov, A, Grundtvig, P, Lang, I, Massidda, B, Van De Velde CH, Gervasio, Mh, Tengrup, I, Tennvall, L, Goodman, S, Modgill, Vk, Vorobiof, Da, Mickiewicz, E, Chirgwin, J, Focan, C, Albin, N, Contu, Aa, Svensson, Jh, Borghede, G, Källström, Ac, Forbes, Jf, Hurtz, Hj, Tubiana Hulin, M, Viens, P, Scanni, A, Arnoldi, E, Nastasi, G, Bottini, A, Alquati, P, Muscat, V, Brincat, S, Holmen, K, Amaral, N, Moreno, I, Trask, C, Robinson, A, Mcintyre, K, Otsuka, A, Hohaus, B, Hoefig, G, Georgoulias, V, Salvagni, S, Bidin, L, Artioli, F, Engan, T, Benedikstsson, Kp, Campbell, I, Harvey, V, Zimbler, H, Mrsic Krmpotic, Z, Canon, Jl, Tchilingirov, Pv, Buser, K, Bolanca, A, Reztke, U, Rhein, U, Jouve, M, Mullins, G, Vesentini, L, Gallo, L, Merlini, L, Decensi, A, Carreca, I, Van Tienhoven, G, Börjesson, B, Hansen, J, Koza, I, Arcusa, A, Inoriza, A, Pelegri, A, Eremin, O, Modiano, Mr, Anthony, S, Donat, D, Richardet, E, Kochli, O, Zeißig, P, Gauch, G, Aabo, K, Fumoleau, P, Erdkamp, Fl, Lovén, L, Jönsson, Pe, Perren, T, Stuart, N, Galindo, E, Marek, Bj, Salmon, Jp, Dohollou, N, Thompson, R, Folco, U, Rosa, A, Tonato, M, Heijmans, Gj, Koralewski, P, Bång, H, Lescure, Ar, Carrato, A, Martin, M, Neave, F, Howell, T, Savin, M, Loesch, D, Hannois, A, Mohr, A, Laube, T, Omar, S, Bonneterre, J, Servent, V, Danese, S, Sertoli, Mr, Butzelaar, Rm, Steller, Ep, Gomez, H, Skoog, P, Alvarez, I, Aguilar, Ea, Giner, Jl, Yosef, Hm, Barrett Lee, P, Buzdar, Au, George, T, Olivaires, J, Vsianska, M, Köhler, U, Lindeløv, B, Toftdahl, Db, Nielsen, Eb, Veyret, C, Castera, D, Kerbrat, P, Vassilaros, P, Yeo, W, Boni, C, Aitini, E, Luporini, G, Herben, Mg, Espelid, H, Dahl, S, Ingvar, C, Meana, A, Pico, C, Garcia, Am, Agrawal, Rk, Gruenberg, D, Nunez de Pierro, A, Gill, G, Nogaret, Jm, Honhon, B, Wassenaar, H, Nielander, R, Warnier, P, Sessa, C, Padrik, P, Guastalla, Jp, Serin, D, Jaubert, D, Dank, M, Given, Fh, Mascia, V, De Fraia, E, Silingardi, V, Conte, Pf, Labianca, R, Tondini, C, Bagnulo, A, Gardani, G, Wils, J, Liem, G, Nuytinck, Jk, Formoe, E, Ambré, T, Alés, J, Aramburo, P, Mansi, J, Graham, J, Joffe, J, Sainsbury, J, Stone, J, Good, Rh, Cartwright, T, Werner, Id, Murray, E, Beith, J, Tigges, Fj, Bojko, P, Sandberg, E, Jensen, B, Lotz, Jp, Carney, D, Shapira, J, Neumann, A, Goldhirsch, A, Dicato, M, de Graaf, H, Maartense, E, Burghouts, J, Cassinello, J, Jones, A, Gaffney, C, Blum, R, Abdi, E, Becquart, D, Dirix, L, Janssens, J, Nmarschner, N, Blaska Jaulerry, B, Prevot, G, Mirah Lev, L, Shani, A, Baruch, Nb, Peretz, T, Gips, M, Cognetti, F, Carlini, P, Nortier, Jw, Huinink D, ten B., Roussel, Jg, Unneberg, K, Kylberg, F, Hovind, H, Nestvold, T, Fogelkvist, R, Due, J, Muller, S, Gilligan, D, Russel, S, Mcaleer, J, Yiangou, C, Foote, L, Schottstaedt, M, Holmes, Fa, Wainstein, R, Contreras, O, Martinez, J, Della Fiorentina, S, Beslija, S, Vermorken, Jb, Thirion, M, Fraikin, J, Castiglione, M, Jäger, W, Fasching, P, Fabriz, H, Neis, K, Kirschbaum, M, Labat, Jp, Dupuis, O, Bernard, J, Datchary, J, Provencal, J, Allain, P, Clerico, M, Lopez, M, Nalli, G, Aspevik, R, Fràguas, A, Curescu, S, Cuevas, Jm, Oltra, A, Bradley, C, Kapoor, R, Akbain, S, Croghan, Mk, Modiano, M, Taetle, R, Beale, P, Gobert, P, Bondue, H, Böhm, R, Møller, Ka, Brettes, Jp, Netter, G, Grogan, L, Klein, B, Botta, M, Barni, S, Van Meerwijk, I, Kåresen, R, Godes, J, Aramburo, A, Jara, C, Zanger, B, Fleagle, Jt, Greenspan, A, Marschke, R, Medgyesy, Dc, Garbo, L., CCA -Cancer Center Amsterdam, and Radiotherapy

Subjects
medicine.medical_specialty, Population, Breast Neoplasms, Disease-Free Survival, chemistry.chemical_compound, Breast cancer, Exemestane, Internal medicine, Surveys and Questionnaires, medicine, Clinical endpoint, Humans, Carpal tunnel syndrome, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Aromatase Inhibitors, Hazard ratio, Middle Aged, medicine.disease, Carpal Tunnel Syndrome, Surgery, Musculoskeletal Abnormalities, Androstadienes, Postmenopause, Tamoxifen, Treatment Outcome, Oncology, chemistry, Hormonal therapy, Female, business, medicine.drug
Abstract

BACKGROUND: Aromatase inhibitors are more effective than is tamoxifen in prevention of breast-cancer recurrence, but at the expense of increased musculoskeletal side-effects, such as carpal tunnel syndrome. The aim of this study was to assess risk factors and the prognostic value of musculoskeletal symptoms during treatment with the steroidal aromatase inhibitor exemestane or with tamoxifen after 2-3 years of tamoxifen. METHODS: In the Intergroup Exemestane Study, postmenopausal women treated for early invasive breast cancer who remained disease free and on treatment after 2-3 years of tamoxifen were randomised to switch to exemestane or to continue tamoxifen for the remainder of the 5-year period of endocrine treatment. The primary endpoint for this retrospective analysis was occurrence of carpal tunnel syndrome and any musculoskeletal events, analysed in the safety population, which consisted of all patients who had received any trial treatment. As well as case-report forms, questionnaires were distributed retrospectively to gain more details of cases of carpal tunnel syndrome. The relation between musculoskeletal symptoms reported by 6 months from randomisation and survival from 9 months onwards was assessed by Cox proportional hazards models. The trial is registered, number ISRCTN11883920. It has completed accrual and follow-up is continuing for enrolled participants. FINDINGS: After a median follow-up of 91·0 months (IQR 83·0-99·2), carpal tunnel syndrome had been reported for 66 (2·8%) of 2319 patients in the exemestane group compared with 13 (0·6%) of 2338 in the tamoxifen group (odds ratio [OR] 5·23, 99% CI 2·39-11·49; p

Published
2012

68. Heating Induced by Therapeutic Ultrasound in the Presence of Magnetic Nanoparticles

Author

Kaczmarek, Katarzyna, Hornowski, Tomasz, Kubovčíková, Martina, Timko, Milan, Koralewski, Marceli, and Józefczak, Arkadiusz

Abstract

The efficiency of ultrasound hyperthermia for anti-cancer treatments such as radiotherapy or chemotherapy can be improved by using sonosensitizers, which are materials that enhance the attenuation and dissipation of acoustic energy. We propose the use of magnetic nanoparticles as sonosensitizers because of their biocompatibility, nontoxicity, and common use in several medical applications. A magnetic material was synthetized and then incorporated in the form of a magnetic fluid in agar tissue-mimicking phantoms. Ultrasound hyperthermia studies were conducted at various ultrasound frequencies and concentrations of magnetic nanoparticles in the phantoms. The theoretical modeling based on a heat transfer equation and the experimental results show good agreement and confirm that the temperature rise during ultrasound heating in tissue-mimicking phantoms doped with sonosensitizers is greater than that in a pure agar phantom. Furthermore, on the basis of Pennes’ bio-heat equation, which takes into consideration the blood perfusion and metabolic heat, the thermal dose and lesion shapes after sonication were determined for a hypothetical tissue.

Published
2018
Full Text
View/download PDF

69. Morphology and Magnetic Structure of the Ferritin Core during Iron Loading and Release by Magnetooptical and NMR Methods

Author

Koralewski, Marceli, Balejc?i´kova´, Lucia, Mitro´ova´, Zuzana, Pochylski, Mikolaj, Baranowski, Mikolaj, and Kopc?ansky´, Peter

Abstract

Ferritins are proteins, which serve as a storage and transportation capsule for iron inside living organisms. Continuously charging the proteins with iron and releasing it from the ferritin is necessary to assure proper management of these important ions within the organism. On the other hand, synthetic ferritins have great potential for biomedical and technological applications. In this work, the behavior of ferritin during the processes of iron loading and release was examined using multiplicity of the experimental technique. The quality of the protein’s shell was monitored using circular dichroism, whereas the average size and its distribution were estimated from dynamic light scattering and transmission electron microscopy images, respectively. Because of the magnetic behavior of the iron mineral, a number of magnetooptical methods were used to gain information on the iron core of the ferritin. Faraday rotation and magnetic linear birefringence studies provide evidence that the iron loading and the iron-release processes are not symmetrical. The spatial organization of the mineral within the protein’s core changes depending on whether the iron was incorporated into or removed from the ferritin’s shell. Magnetic optical rotatory dispersion spectra exclude the contribution of the Fe(II)-composed mineral, whereas joined magnetooptical and nuclear magnetic resonance results indicate that no mineral with high magnetization appear at any stage of the loading/release process. These findings suggest that the iron core of loaded/released ferritin consists of single-phase, that is, ferrihydrite. The presented results demonstrate the usefulness of emerging magnetooptical methods in biomedical research and applications.

Published
2018
Full Text
View/download PDF

71. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Author

Ramalingam, S., primary, Crawford, J., additional, Chang, A., additional, Manegold, C., additional, Perez-Soler, R., additional, Douillard, J.-Y., additional, Thatcher, N., additional, Barlesi, F., additional, Owonikoko, T., additional, Wang, Y., additional, Pultar, P., additional, Zhu, J., additional, Malik, R., additional, Giaccone, G., additional, Della-Fiorentina, S., additional, Begbie, S., additional, Jennens, R., additional, Dass, J., additional, Pittman, K., additional, Ivanova, N., additional, Koynova, T., additional, Petrov, P., additional, Tomova, A., additional, Tzekova, V., additional, Couture, F., additional, Hirsh, V., additional, Burkes, R., additional, Sangha, R., additional, Ambrus, M., additional, Janaskova, T., additional, Musil, J., additional, Novotny, J., additional, Zatloukal, P., additional, Jakesova, J., additional, Klenha, K., additional, Roubec, J., additional, Vanasek, J., additional, Fayette, J., additional, Bennouna-Louridi, J., additional, Chouaid, C., additional, Mazières, J., additional, Vallerand, H., additional, Robinet, G., additional, Souquet, P.-J., additional, Spaeth, D., additional, Schott, R., additional, Lena, H., additional, Martinet, Y., additional, El Kouri, C., additional, Baize, N., additional, Scherpereel, A., additional, Molinier, O., additional, Fuchs, F., additional, Josten, K.M., additional, Marschner, N., additional, Schneller, F., additional, Overbeck, T., additional, Thomas, M., additional, von Pawel, J., additional, Reck, M., additional, Schuette, W., additional, Hagen, V., additional, Schneider, C.-P., additional, Georgoulias, V., additional, Varthalitis, I., additional, Zarogoulidis, K., additional, Syrigos, K., additional, Papandreou, C., additional, Bocskei, C., additional, Csanky, E., additional, Juhasz, E., additional, Losonczy, G., additional, Mark, Z., additional, Molnar, I., additional, Papai-Szekely, Z., additional, Tehenes, S., additional, Vinkler, I., additional, Almel, S., additional, Bakshi, A., additional, Bondarde, S., additional, Maru, A., additional, Pathak, A., additional, Pedapenki, R.M., additional, Prasad, K., additional, Prasad, S.V.S.S., additional, Kilara, N., additional, Gorijavolu, D., additional, Deshmukh, C.D., additional, John, S., additional, Sharma, L.M., additional, Amoroso, D., additional, Bajetta, E., additional, Bidoli, P., additional, Bonetti, A., additional, De Marinis, F., additional, Maio, M., additional, Passalacqua, R., additional, Cascinu, S., additional, Bearz, A., additional, Bitina, M., additional, Brize, A., additional, Purkalne, G., additional, Skrodele, M., additional, Baba, A.A., additional, Ratnavelu, K., additional, Saw, M.H., additional, Samson-Fernando, M.C., additional, Ladrera, G.E., additional, Jassem, J., additional, Koralewski, P., additional, Serwatowski, P., additional, Krzakowski, M., additional, Cebotaru, C., additional, Filip, D., additional, Ganea-Motan, D.E., additional, Ianuli, C.H., additional, Manolescu, I.G., additional, Udrea, A., additional, Burdaeva, O., additional, Byakhov, M., additional, Filippov, A., additional, Lazarev, S., additional, Mosin, I., additional, Orlov, S., additional, Udovitsa, D., additional, Khorinko, A., additional, Protsenko, S., additional, Lim, H.L., additional, Tan, Y.O., additional, Tan, E.H., additional, Bastus Piulats, R., additional, Garcia-Foncillas, J., additional, Valdivia, J., additional, de Castro, J., additional, Domine Gomez, M., additional, Kim, S.W., additional, Lee, J.-S., additional, Kim, H.K., additional, Lee, J.S., additional, Shin, S.W., additional, Kim, D.-W., additional, Kim, Y.-C., additional, Park, K.C., additional, Chang, C.-S., additional, Chang, G.-C., additional, Goan, Y.-G., additional, Su, W.-C., additional, Tsai, C.-M., additional, Kuo, H.-P., additional, Benekli, M., additional, Demir, G., additional, Gokmen, E., additional, Sevinc, A., additional, Haigentz, M., additional, Agarwal, M., additional, Pandit, S., additional, Araujo, R., additional, Vrindavanam, N., additional, Bonomi, P., additional, Berg, A., additional, Wade, J., additional, Bloom, R., additional, Amin, B., additional, Camidge, R., additional, Hill, D., additional, Rarick, M., additional, Flynn, P., additional, Klein, L., additional, Lo Russo, K., additional, Neubauer, M., additional, Richards, P., additional, Ruxer, R., additional, Savin, M., additional, Weckstein, D., additional, Rosenberg, R., additional, Whittaker, T., additional, Richards, D., additional, Berry, W., additional, Ottensmeier, C., additional, Dangoor, A., additional, Steele, N., additional, Summers, Y., additional, Rankin, E., additional, Rowley, K., additional, Giridharan, S., additional, Kristeleit, H., additional, Humber, C., additional, and Taylor, P., additional

Published
2013
Full Text
View/download PDF

73. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining.

Author

Siena, S., primary, Tabernero, J., additional, Cunningham, D., additional, Koralewski, P., additional, Ruff, P., additional, Rother, M., additional, Johnson, C. W., additional, Zhang, A., additional, Gansert, J. L., additional, and Douillard, J., additional

Published
2010
Full Text
View/download PDF

82. 4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)

Author

Bracarda, S., primary, Koralewski, P., additional, Pluzanska, A., additional, Ravaud, A., additional, Szczylik, C., additional, Chevreau, C., additional, Filipek, M., additional, Melichar, B., additional, Moore, N., additional, and Escudier, B., additional

Published
2007
Full Text
View/download PDF

89. Plants on the move: Assisted migration of forest trees in the face of climate change.

Author

Koralewski, Tomasz E., Wang, Hsiao-Hsuan, Grant, William E., and Byram, Thomas D.

Subjects
PLANT migration, VEGETATION & climate, PLANT species, EFFECT of temperature on plants, DECISION support systems
Abstract

Climate change is impacting distributions of both fauna and flora, including many crops. In order to ensure the health and vigor of the species we depend upon for food and fiber, assisted migration strategies may need to be implemented. This is especially true for long-lived forest trees. Multinomial logit regression was used to develop a Categorical Universal Response Function (CURF) to delineate deployment zones for loblolly pine ( Pinus taeda L.) using 15-year measurements from the Western Gulf Forest Tree Improvement Program (WGFTIP) Geographic Seed Source Study (GSSS). The CURF uses performance categories for the response variable, and the model assigns the probabilities with which the performance for a given seed source will fall into these various categories. First and second powers of minimum temperature of the coldest month, summer precipitation, and variation measures of these two metrics at both the seed source site of origin and the test location were used as independent variables. Planted tree volume, accounting for both survival and growth, was used as the response variable. Model performance was good, with the AUC score ranging from 0.785 to 0.808, depending on (1) whether or not the variable interactions were included and (2) the variable selection criterion used (AIC or BIC). Resulting models were then applied to historic weather patterns to illustrate inferred deployment zones for three seed sources. The projected performance generally agreed with the current consensus on loblolly pine seed movement guidelines. The models developed here can be readily implemented in a Decision Support System as they (1) suggest sets of adapted loblolly pine families from which foresters can choose based on local knowledge, (2) can be easily expanded to include other variables, and (3) can be applied to outputs from projected climate scenarios to extrapolate into the future. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

91. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)

Author

Cassidy, J., primary, Bjarnason, G. A., additional, Hickish, T., additional, Topham, C., additional, Provencio, M., additional, Bodoky, G., additional, Landherr, L., additional, Koralewski, P., additional, Lopez-Vivanco, G., additional, and Said, G., additional

Published
2006
Full Text
View/download PDF

92. O-085 Phase III trial of the protein kinase C α (PKCα) antisense oligonucleotide Aprinocarsen plus gemcitabine/cisplatin versus gemcitabine/cisplatin alone in advanced stage non-small cell lung cancer (NSCLC): Updated results of a randomized phase III trial

Author

Gandara, D., primary, Douillard, J., additional, Koralewski, P., additional, Manegold, C., additional, Smit, E., additional, Reyes, J., additional, Chang, G., additional, Obasaju, C., additional, Peterson, P., additional, and Paz-Ares, L., additional

Published
2005
Full Text
View/download PDF

93. Randomized phase III trial of gemcitabine/cisplatin (GC) and protein kinase C α (PKCα) antisense oligonucleotide aprinocarsen in patients (pts) with advanced stage non-small cell lung cancer (NSCLC)

Author

Paz-Ares, L., primary, Douillard, J.-Y., additional, Koralewski, P., additional, Manegold, C., additional, Smit, E. F., additional, Reyes, J. M., additional, Chang, G. C., additional, John, W. J., additional, Peterson, P., additional, and Gandara, D. R., additional

Published
2005
Full Text
View/download PDF

95. Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study)

Author

Pluzanska, A., primary, Mainwaring, P., additional, Cassidy, J., additional, Utracka-Hutka, B., additional, Zalucki, J., additional, Glynne-Jones, R., additional, Koralewski, P., additional, Bridgewater, J., additional, Wasan, H., additional, and Cunningham, D., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results